Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- ChecktodayChange DetectedThe page now displays a government funding lapse notice and the site version was updated to Revision: v3.4.1, which are administrative updates and do not affect core study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check7 days agoChange DetectedShow glossary control added and metadata labels revised (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) replacing the previous QC/Revision label. No core study content, eligibility criteria, or results are affected; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows the updated site revision: Revision: v3.3.4, replacing the prior v3.3.3 tag. This is a minor backend update that does not alter study details.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded a Locations section with a Washington listing and updated the revision to v3.3.3. Removed the older Washington Locations header and the HHS Vulnerability Disclosure section.SummaryDifference0.2%

- Check72 days agoChange DetectedMinor metadata updates: a PubMed-related note was added and the page revision 3.3.2 is listed, while the PubMed description was shortened and the previous revision 3.2.0 is no longer shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoved the government funding notice about updates and operating status; the study details content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.